Chapter 9
Polygenic Risk Scores and Precision Medicine: Predicting Right Heart Disease Before Symptoms Appear
Medicine has traditionally focused on diagnosing diseases after symptoms develop. A patient experiences chest pain, shortness of breath, fatigue, or palpitations, undergoes medical evaluation, receives a diagnosis, and then begins treatment. While this reactive approach has saved countless lives, it often identifies disease only after significant damage has already occurred. Advances in genetics, artificial intelligence, and large-scale population studies are now transforming healthcare from a reactive discipline into a predictive one. One of the most promising developments driving this transformation is the Polygenic Risk Score (PRS).
A polygenic risk score estimates an individual’s inherited susceptibility to a disease by combining the effects of many genetic variants spread throughout the genome. Unlike rare inherited disorders caused by mutations in a single gene, most common cardiovascular diseases result from the combined influence of hundreds or even thousands of genetic variants, each contributing a very small effect. When these small effects are added together, they provide valuable information about an individual’s overall genetic predisposition.
The concept of polygenic inheritance recognizes that complex diseases rarely have a single genetic cause. Conditions such as hypertension, coronary artery disease, atrial fibrillation, heart failure, pulmonary hypertension, and dilated cardiomyopathy arise from interactions among numerous genes, environmental exposures, aging, and lifestyle factors. Each genetic variant may increase or decrease disease risk by only a fraction, but together they can significantly influence long-term cardiovascular health.
Genome-wide association studies have identified thousands of genetic variants associated with cardiovascular traits. Some influence blood pressure, while others affect cholesterol metabolism, cardiac rhythm, myocardial structure, inflammatory responses, or vascular function. Variants associated with right ventricular size, pulmonary artery diameter, and right ventricular ejection fraction have also been discovered through studies combining cardiac MRI with artificial intelligence. Polygenic risk scores integrate these discoveries into a single quantitative measure.
Constructing a polygenic risk score begins with results obtained from genome-wide association studies. Researchers identify genetic variants significantly associated with a particular phenotype, such as right ventricular ejection fraction or dilated cardiomyopathy. Each variant is assigned a statistical weight based on the strength of its association with the trait. An individual’s DNA is then analyzed to determine which versions of these variants they carry. The weighted effects of thousands of variants are combined mathematically to generate an overall genetic risk score.
Although the calculations involve sophisticated statistical methods, the underlying concept is straightforward. A person who inherits a larger number of risk-associated genetic variants receives a higher polygenic score, indicating greater inherited susceptibility. Conversely, an individual carrying fewer risk variants receives a lower score. Importantly, the score estimates probability rather than certainty. A high polygenic risk score does not guarantee disease, nor does a low score eliminate risk.
One of the most significant applications of polygenic risk scoring in cardiovascular medicine involves dilated cardiomyopathy (DCM). Dilated cardiomyopathy is characterized by enlargement of the heart chambers, particularly the ventricles, accompanied by reduced pumping ability. Although some cases result from rare inherited mutations, many patients have no identifiable single-gene cause. Large-scale genetic studies have shown that common genetic variants collectively influence susceptibility to dilated cardiomyopathy.
Recent research has demonstrated that a polygenic predictor based on right ventricular ejection fraction (RVEF) is associated with future development of dilated cardiomyopathy. Individuals with genetically predicted lower right ventricular function showed a significantly increased likelihood of developing the disease during follow-up. Importantly, this association remained significant even after accounting for polygenic scores based on left ventricular measurements, suggesting that right ventricular genetics provide unique and independent information about cardiovascular risk.
This finding has important biological implications. Traditionally, cardiologists have focused primarily on the left ventricle because of its central role in systemic circulation. However, emerging evidence indicates that inherited variation affecting the right ventricle contributes independently to disease susceptibility. The right ventricle is therefore not merely a passive partner of the left heart but possesses its own genetic architecture influencing lifelong cardiovascular health.
Polygenic risk scores have also shown promise in predicting other cardiovascular disorders. Scores have been developed for coronary artery disease, atrial fibrillation, hypertension, ischemic stroke, heart failure, and sudden cardiac death. Individuals within the highest percentiles of these scores often exhibit disease risks several times greater than those with average genetic profiles. Such information may eventually guide preventive strategies long before symptoms appear.
The predictive value of polygenic risk scores increases substantially when combined with traditional clinical risk factors. Age, sex, smoking status, blood pressure, diabetes, cholesterol levels, obesity, physical activity, and family history remain powerful predictors of cardiovascular disease. Rather than replacing these established factors, polygenic scores complement them by identifying inherited risk that may not be evident from clinical evaluation alone.
Consider two individuals of similar age, blood pressure, cholesterol levels, and lifestyle habits. Conventional risk calculators might estimate comparable cardiovascular risk for both individuals. However, if one person carries a substantially higher polygenic risk score for cardiomyopathy or coronary artery disease, earlier screening or more intensive preventive interventions may be justified. In this way, genetic information refines rather than replaces traditional medical assessment.
The emergence of precision medicine reflects this shift toward individualized healthcare. Precision medicine seeks to tailor prevention, diagnosis, and treatment according to each person’s unique combination of genetic, environmental, lifestyle, and clinical characteristics. Instead of applying identical recommendations to every patient, physicians increasingly recognize that individuals differ substantially in disease susceptibility, treatment response, and prognosis.
Cardiac magnetic resonance imaging plays a crucial role in precision cardiology. Artificial intelligence can accurately measure right ventricular volume, right atrial size, pulmonary artery diameter, myocardial mass, and ejection fraction. These quantitative imaging biomarkers, when integrated with polygenic risk scores, provide a far more comprehensive assessment of cardiovascular health than either approach alone.
For example, an individual with a high genetic risk score but normal cardiac MRI findings may benefit from periodic monitoring rather than immediate intervention. Conversely, subtle MRI abnormalities detected in a genetically high-risk individual could prompt earlier treatment before irreversible myocardial damage occurs. Such personalized strategies may significantly improve long-term outcomes.
Polygenic risk scores also have potential applications in congenital heart disease. Although many severe congenital defects arise from rare mutations or chromosomal abnormalities, common genetic variants likely influence susceptibility as well. Future prenatal genetic screening may combine polygenic scores with fetal imaging to identify pregnancies requiring specialized monitoring or delivery at tertiary cardiac centers. However, substantial research remains necessary before these approaches become routine clinical practice.
Another promising application involves pharmacogenomics, the study of how genetic variation influences medication response. Individuals differ considerably in their responses to cardiovascular drugs such as anticoagulants, statins, beta-blockers, and antiarrhythmic agents. Integrating polygenic information with pharmacogenomic testing may help physicians select the safest and most effective medications while minimizing adverse effects.
Artificial intelligence further enhances precision medicine by integrating multiple sources of information simultaneously. Modern machine learning models can analyze genetic data, cardiac MRI measurements, laboratory results, electrocardiograms, electronic health records, wearable sensor data, and lifestyle information within a single predictive framework. These multidimensional models often outperform traditional statistical approaches because they recognize complex interactions among diverse biological variables.
Despite their considerable promise, polygenic risk scores have important limitations. Most current scores were developed using populations of predominantly European ancestry. Because genetic variation differs across populations, scores developed in one ethnic group may perform less accurately in others. Expanding genomic research to include diverse populations is therefore essential for ensuring equitable implementation of precision medicine worldwide.
Another limitation is that polygenic risk scores capture only inherited genetic variation. They do not account for environmental influences such as smoking, diet, exercise, air pollution, occupational exposures, psychological stress, or socioeconomic conditions, all of which substantially affect cardiovascular health. Epigenetic modifications, which alter gene expression without changing DNA sequence, are likewise not fully reflected in current polygenic models.
Interpretation also requires careful communication. A high polygenic risk score does not mean disease is inevitable. Many individuals with elevated genetic risk remain healthy throughout life, particularly if they maintain favorable lifestyles. Likewise, people with low genetic risk may still develop cardiovascular disease because of adverse environmental exposures or acquired medical conditions. Genetic risk represents probability rather than destiny.
Ethical considerations accompany the growing use of genomic prediction. Genetic information is deeply personal and raises important questions regarding privacy, informed consent, insurance discrimination, employment practices, and psychological well-being. Robust legal protections and ethical guidelines are necessary to ensure that genetic data are used responsibly and benefit patients without creating new forms of discrimination or inequity.
Healthcare systems must also address practical challenges before widespread implementation. Genetic testing requires laboratory infrastructure, specialized expertise, standardized interpretation, and integration with electronic medical records. Clinicians need appropriate education to understand polygenic risk scores and communicate their meaning effectively to patients. Decision-support systems powered by artificial intelligence may assist physicians by translating complex genomic information into clinically meaningful recommendations.
Research continues to improve polygenic prediction models. New statistical methods incorporate millions of genetic variants while accounting for interactions among genes and environmental factors. Multi-omics approaches integrate genomics with transcriptomics, proteomics, metabolomics, and epigenomics, providing a more comprehensive understanding of disease biology. As these technologies mature, predictive accuracy is expected to increase substantially.
The future of cardiovascular medicine may involve routine genomic screening early in adulthood, followed by individualized prevention plans based on genetic risk, imaging findings, laboratory biomarkers, and lifestyle assessment. Individuals with elevated inherited risk could receive earlier cardiac MRI examinations, personalized exercise programs, dietary counseling, more frequent monitoring, or preventive medications long before symptoms develop. Such proactive strategies have the potential to reduce the burden of heart failure, cardiomyopathy, and sudden cardiac death.
The integration of polygenic risk scores with artificial intelligence, advanced imaging, and precision medicine represents one of the most exciting developments in modern cardiology. Rather than simply treating established disease, clinicians are moving toward predicting risk, preventing disease progression, and personalizing healthcare for every individual. Studies involving the right heart have demonstrated that inherited variation in right ventricular function contributes independently to future cardiovascular disease, reinforcing the importance of studying both sides of the heart as distinct yet interconnected biological systems.
As our understanding of cardiovascular genetics continues to expand, polygenic risk scores will become increasingly valuable tools for identifying individuals at risk before irreversible damage occurs. Combined with deep learning, cardiac MRI, and molecular biology, they provide a foundation for a new era of predictive and preventive cardiology. In the next chapter, we will explore how these scientific advances are being translated into clinical practice, examining current applications in diagnosis, patient management, therapeutic decision-making, and the future of personalized cardiovascular care.
